• Axon Enterprise recently reported that its revenue has grown by over 30% in every quarter for the past two years, while securing its largest-ever individual device order and multiple eight-figure government contracts alongside a roughly 5% operating margin.
• At the same time, Axon’s Dedrone counter-drone business has quickly become one of its largest product lines, surpassing US$100 million in quarterly revenue and gaining a place in a potential US$1.50 billion government counter-drone program, highlighting how drone defense is becoming a core pillar of its public safety ecosystem.
• We’ll now examine how Dedrone’s rapid rise within Axon’s portfolio could influence the company’s broader investment narrative and future growth mix.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Axon Enterprise Investment Narrative Recap

To own Axon, you likely need to believe in its role as a core provider of modern public safety technology, with growing software and device ecosystems. The latest results, with revenue consistently growing over 30% and Dedrone surpassing US$100 million in quarterly revenue, reinforce that thesis but do not remove key risks around dependence on government budgets and margin pressure as the business mix shifts and operating margin sits near 5%.

Among recent announcements, Axon’s selection as a vendor in a potential US$1.50 billion government counter drone program is especially relevant here. It directly ties Dedrone’s momentum to a large, multi year public safety spending pool, which could strengthen Axon’s position in drones and airspace awareness while intensifying exposure to the same government funding and regulatory risks that underpin the current catalyst narrative.

Yet while Dedrone’s success looks encouraging, investors should still be aware that...

Axon Enterprise's narrative projects $6.3 billion revenue and $516.8 million earnings by 2029.

Uncover how Axon Enterprise's forecasts yield a $662.04 fair value, a 5% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already expected revenue near US$7.1 billion and earnings around US$823.5 million by 2029, so if you worry about tighter law enforcement budgets you may see this new Dedrone momentum very differently.

Explore 6 other fair value estimates on Axon Enterprise - why the stock might be worth as much as 10% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Axon Enterprise research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Axon Enterprise research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Axon Enterprise's overall financial health at a glance.

Interested In Other Possibilities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.